Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 in overweight or obesity
NCT06371326Phase 1Completed
- Sponsor
- QL Biopharm
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing ZT002 Injection with ZT002 Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 270 days and Serious Adverse Events at 270 days. Started Nov 2023; status: completed.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06371326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371326.